Spatial distribution of dysplasia in Barrett’s esophagus segments before and after endoscopic ablation therapy: a meta-analysis

Shashank Garg; Jesse Xie; Sumant Inamdar; Sheila L. Thomas; Arvind J. Trindade

doi:10.1055/a-1195-1000

Endoscopy, Table of Contents

Endoscopy 2021; 53(01): 6-14
DOI: 10.1055/a-1195-1000

Systematic review

Spatial distribution of dysplasia in Barrett’s esophagus segments before and after endoscopic ablation therapy: a meta-analysis

Shashank Garg‡^*

¹Division of Gastroenterology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

,

Jesse Xie‡^*

²Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

,

Sumant Inamdar

¹Division of Gastroenterology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

,

Sheila L. Thomas

³Education and Research Services, UAMS Library, Little Rock, Arkansas, USA

,

Arvind J. Trindade

⁴Division of Gastroenterology, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park, New York, USA

› Author Affiliations

Abstract

Background Dysplasia in Barrett’s esophagus (BE) is focal and difficult to locate. The aim of this meta-analysis was to understand the spatial distribution of dysplasia in BE before and after endoscopic ablation therapy.

Methods A systematic search was performed of multiple databases to July 2019. The location of dysplasia prior to ablation was determined using a clock-face orientation (right or left half of the esophagus). The location of the dysplasia post-ablation was classified as within the tubular esophagus or at the top of the gastric folds (TGF).

Results 13 studies with 2234 patients were analyzed. Pooled analysis from six studies (819 lesions in 802 patients) showed that before ablation, dysplasia was more commonly located in the right half versus the left half (odds ratio [OR] 4.3; 95 % confidence interval [CI] 2.33 – 7.93; P < 0.001). Pooled analysis from seven studies showed that dysplasia after ablation recurred in 101 /1432 patients (7.05 %; 95 %CI 5.7 % – 8.4 %). Recurrence of dysplasia was located more commonly at the TGF (n = 68) than in the tubular esophagus (n = 34; OR 5.33; 95 %CI 1.75 – 16.21; P = 0.003). Of the esophageal lesions, 90 % (27 /30) were visible, whereas only 46 % (23 /50) of the recurrent dysplastic lesions at the TGF were visible (P < 0.001).

Conclusion Before ablation, dysplasia in BE is found more frequently in the right half of the esophagus versus the left. Post-ablation recurrence is more commonly found in the TGF and is non-visible, compared with the tubular esophagus, which is mainly visible.

Full Text

References

References
1 Spechler SJ, Souza RF. Barrett’s Esophagus. NEJM 2014; 371: 836-845
2 Trindade AJ, Navaneethan U, Aslanian HR. et al. Advances in the diagnosis and surveillance of Barrett’s esophagus (with videos). Gastrointest Endosc 2019; 90: 325-334
3 Anandasabapathy S. Advanced imaging in Barrett’s esophagus: are we ready to relinquish the random?. Clin Gastroenterol Hepatol 2013; 11: 1571-1572
4 Antony A, Pohanka C, Keogh S. et al. Adherence to quality indicators in endoscopic surveillance of Barrett’s esophagus and correlation to dysplasia detection rates. Clin Res Hepatol Gastroenterol 2018; 42: 591-596
5 Sharma P, Katzka DA, Gupta N. et al. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology 2015; 149: 1599-1606
6 Cerrone SA, Trindade AJ. Advanced imaging in surveillance of Barrett’s esophagus: Is the juice worth the squeeze?. World J Gastroenterol 2019; 25: 3108-3115
7 Qumseya BJ, Wang H, Badie N. et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 2013; 11: 1562-70.e1-e2
8 Waterhouse DJ, Fitzpatrick CRM, di Pietro M. et al. Emerging optical methods for endoscopic surveillance of Barrett’s oesophagus. Lancet Gastroenterol Hepatol 2018; 3: 349-362
9 Alshelleh M, Inamdar S, McKinley M. et al. Incremental yield of dysplasia detection in Barrett’s esophagus using volumetric laser endomicroscopy with and without laser marking compared with a standardized random biopsy protocol. Gastrointest Endosc 2018; 88: 35-42
10 Sharma P, Falk GW, Weston AP. et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572
11 Bibbò S, Ianiro G, Ricci R. et al. Barrett’s oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. Dig Liver Dis 2016; 48: 1043-1047
12 Enestvedt BK, Lugo R, Guarner-Argente C. et al. Location, location, location: does early cancer in Barrett’s esophagus have a preference?. Gastrointest Endosc 2013; 78: 462-467
13 Pech O, Gossner L, Manner H. et al. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy 2007; 39: 588-593
14 Kariyawasam VC, Bourke MJ, Hourigan LF. et al. Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett’s esophagus. Gastrointest Endosc 2012; 75: 938-944
15 Cotton CC, Duits LC, Wolf WA. et al. Spatial predisposition of dysplasia in Barrett’s esophagus segments: a pooled analysis of the SURF and AIM dysplasia trials. Am J Gastroenterol 2015; 110: 1412-1419
16 Omar M, Thaker AM, Wani S. et al. Anatomic location of Barrett’s esophagus recurrence after endoscopic eradication therapy: development of a simplified surveillance biopsy strategy. Gastrointest Endosc 2019; 90: 395-403
17 Eluri S, Earasi AG, Moist SE. et al. Prevalence and incidence of intestinal metaplasia and dysplasia of gastric cardia in patients with Barrett’s esophagus after endoscopic therapy. Clin Gastroenterol Hepatol 2020; 18: 82-88.e1
18 Sami SS, Ravindran A, Kahn A. et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut 2019; 68: 1379-1385
19 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700-b2700
20 Bahin FF, Jayanna M, Hourigan LF. et al. Long-term outcomes of a primary complete endoscopic resection strategy for short-segment Barrett’s esophagus with high-grade dysplasia and/or early esophageal adenocarcinoma. Gastrointest Endosc 2016; 83: 68-77
21 Pech O, Gossner L, Manner H. et al. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy 2007; 39: 588-593
22 Cassani L, Sumner E, Slaughter JC. et al. Directional distribution of neoplasia in Barrett’s esophagus is not influenced by distance from the gastroesophageal junction. Gastrointest Endosc 2013; 77: 877-882
23 Conio M, Fisher DA, Blanchi S. et al. One-step circumferential endoscopic mucosal cap resection of Barrett’s esophagus with early neoplasia. Clin Res Hepatol Gastroenterol 2014; 38: 81-91
24 Jego M, Volant A, Faycal J. et al. Prevalence and topography of intestinal metaplasia in columnar lined esophagus. Gastroenterol Clin Biol 2007; 31: 601-606
25 Konda VJA, Gonzalez HabaRuiz M, Koons A. et al. Complete endoscopic mucosal resection is effective and durable treatment for Barrett’s-associated neoplasia. Clin Gastroenterol Hepatol 2014; 12: 2002-2010.e1-e2
26 Mino-Kenudson M, Ban S, Ohana M. et al. Buried dysplasia and early adenocarcinoma arising in Barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol 2007; 31: 403-409
27 Pouw RE, Gondrie JJ, Sondermeijer CM. et al. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg 2008; 12: 1627-1636 ; discussion 1636-1637
28 Yasuda K, Choi SE, Nishioka NS. et al. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett’s esophagus. Dig Dis Sci 2014; 59: 1560-1566
29 Cameron G, Desmond P, Jayasekera C. et al. Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett’s esophagus may not be benign. Endosc Int Open 2016; 04: E849-E858
30 Cotton CC, Wolf WA, Pasricha S. et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc 2015; 81: 1362-1369
31 Halsey KD, Chang JW, Waldt A. et al. Recurrent disease following endoscopic ablation of Barretts high-grade dysplasia with spray cryotherapy. Endoscopy 2011; 43: 844-848
32 Ramay FH, Cui Q, Greenwald BD. Outcomes after liquid nitrogen spray cryotherapy in Barrett’s esophagus–associated high-grade dysplasia and intramucosal adenocarcinoma: 5-year follow-up. Gastrointest Endosc 2017; 86: 626-632
33 Sami SS, Ravindran A, Kahn A. et al. Timeline and location of recurrence following successful ablation in Barrett’s oesophagus: an international multicentre study. Gut 2019; 68: 1379-1385
34 Vaccaro BJ, Gonzalez S, Poneros JM. et al. Detection of intestinal metaplasia after successful eradication of Barrett’s Esophagus with radiofrequency ablation. Dig Dis Sci 2011; 56: 1996-2000
35 Skrobić O, Simić A, Radovanović N. et al. Significance of Nissen fundoplication after endoscopic radiofrequency ablation of Barrett’s esophagus. Surg Endosc 2016; 30: 3802-3807
36 van Vilsteren FGI, Pouw RE, Seewald S. et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011; 60: 765-773
37 Herrero LA, van Vilsteren FGI, Pouw RE. et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett’s esophagus longer than 10 cm. Gastrointest Endosc 2011; 73: 682-690
38 Tan MC, Kanthasamy KA, Yeh AG. et al. Factors associated with recurrence of Barrett’s esophagus after radiofrequency ablation. Clin Gastroenterol Hepatol 2019; 17: 65-72.e5
39 Phoa KN, Pouw RE, van Vilsteren FGI. et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145: 96-104
40 Badreddine RJ, Prasad GA, Wang KK. et al. Prevalence and predictors of recurrent neoplasia after ablation of Barrett’s esophagus. Gastrointest Endosc 2010; 71: 697-703
41 Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett’s high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 2002; 97: 2998-3006
42 Dulai PS, Pohl H, Levenick JM. et al. Radiofrequency ablation for long- and ultralong-segment Barrett’s esophagus: A comparative long-term follow-up study. Gastrointest Endosc 2013; 77: 534-541
43 Bradburn MJ, Deeks JJ, Berlin JA. et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77
44 Efthimiou O, Rücker G, Schwarzer G. et al. Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 2019; 38: 2992-3012
45 Krishnamoorthi R, Singh S, Ragunathan K. et al. Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy: a systematic review and meta-analysis. Gastrointest Endosc 2016; 83: 1090-1106.e3
46 Cotton CC, Wolf WA, Pasricha S. et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett’s esophagus: endoscopic findings and anatomic location. Gastrointest Endosc 2015; 81: 1362-1369
47 Corley DA, Mehtani K, Quesenberry C. et al. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013; 145: 312-319.e1
48 Alshelleh M, Inamdar S, McKinley M. et al. Incremental yield of dysplasia detection in Barrett’s esophagus using volumetric laser endomicroscopy with and without laser marking compared with a standardized random biopsy protocol. Gastrointest Endosc 2018; 88: 35-42
49 ASGE Practice Committee. Qumseya B, Sultan S. et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc 2019; 90: 335-359.e2
50 Winans CS. Manometric asymmetry of the lower-esophageal high-pressure zone. Am J Dig Dis 1977; 22: 348-354
51 Schneider JH, Grund KE, Becker HD. Lower esophageal sphincter measurement in four different quadrants in normals and patients with achalasia. Dis Esophagus 1998; 11: 120-124
52 Katsube T, Adachi K, Furuta K. et al. Difference in localization of esophageal mucosal breaks among grades of esophagitis. J Gastroenterol Hepatol 2006; 21: 1656-1659
53 Shaheen NJ, Falk GW, Iyer PG. et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111: 30-50 ; quiz 51

Supplementary Material

Supplementary material